UAE's Julphar Sends Life-Saving Medicine to Cairo Crash Survivors
- ‘It is our duty to supply medicines to patients in need,’ says Julphar Egypt Senior Director
- Scores of survivors remain in critical condition with serious burns
- 100,000 tubes of MEBO sent to Cairo hospitals
Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has sent more than 100,000 tubes of life-saving MEBO burn ointment to hospitals in Egypt following a train crash in the country’s capital.
The urgent request for medical supplies was made directly to Julphar’s Egypt office by the Egyptian Ministry of Health based on the recommendations of plastic surgeons. Egypt is one of the UAE-based pharmaceutical company’s key markets and MEBO ointment is the leading product in the wound and burn treatment in Egypt.
At least 25 people were killed and dozens more injured after a train crashed at high speed into a barrier at Cairo’s main station, causing its fuel tank to explode. The single railcar was said to have been travelling too fast when it collided head-on with the barrier. Almost 50 people were injured in the crash and require urgent medical treatment.
Dr Magdy Al Saaty, Senior Director of Julphar - Egypt Cluster, said: “We responded immediately to an urgent request to supply a large volume of MEBO ointment to treat the many casualties who have suffered severe burns, many of whom are now in critical condition. As one of the region’s biggest pharmaceutical companies, it is our duty to supply medicines to patients in need and we are working hand in hand with the emergency services and hospital staff to ensure we are able to meet their high demands.
“Our teams on the ground in Egypt are working around the clock to provide any assistance and support. We have allocated extra resources and we remain ready to help in any way we can.”
MEBO Ointment, one of Julphar’s leading products, is an innovative patented formula, composed of a combination of natural ingredients such as ß-Sitosterol, Sesame oil and Beeswax. It has demonstrated its efficacy in acute and chronic wound management and has more than 20 years of success in the region.